Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Fig. 4

Inflammasome-mediated signal transduction pathway. The DNA sensor AIM2 and IFI16 is composed of an N terminal pyrin domain and C terminal HIN-200 domain. Cytosolic DNA induces activation of AIM2 or IFI16. The HIN-200 domain interacts with DNA, while the pyrin domain binds to the pyrin domain of ASC. CARD of ASC binds the CARD of pro-caspase-1, which activates caspase-1. Activated caspase-1 drives cleavage of pro-IL-1β, pro-IL-18, and Gasdermin D. In addition, activated IFI16 can recruit STING to activate IRF3 and NFκB to induce type I interferon

Back to article page